Clarity Pharmaceuticals Ltd

Informe acción ASX:CU6

Capitalización de mercado: AU$2.2b

Clarity Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Michelle Parker

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEOless than a year
Participación del CEO0.3%
Permanencia media de la dirección2.6yrs
Promedio de permanencia en la Junta Directiva4.9yrs

Actualizaciones recientes de la dirección

Recent updates

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Sep 23
We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29
We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24
Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13
Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

CEO

Michelle Parker

less than a year

Permanencia

Ms. Michelle Parker is Executive Director of Clarity Pharmaceuticals Ltd from August 2024 and is its Chief Executive Officer and MD. Ms. Parker joined the Clarity Pharmaceuticals Ltd in June 2018. She serv...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Alan Taylor
Executive Chairman11yrsAU$1.22m4.9%
A$ 110.0m
David Green
Chief Financial Officer2.6yrsAU$273.61ksin datos
Colin Biggin
COO & Non-Independent Executive Directorless than a yearAU$1.02m1.35%
A$ 30.4m
Michelle Parker
CEO, MD & Executive Directorno datasin datos0.34%
A$ 7.6m
Matthew Harris
Chief Scientific Officerno dataAU$241.43k1.89%
A$ 42.5m
Lisa Sadetskaya
Director of Corporate Communications.no datasin datossin datos
Mary Bennett
Head of Human Resourceno datasin datossin datos
Shaemus Gleason
Executive Vice President of Operationsno datasin datossin datos
Othon Gervasio
Chief Medical Officerno datasin datossin datos
Robert Vickery
Company Secretaryno dataAU$268.69ksin datos

2.6yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de CU6 se considera experimentado (2.6 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Alan Taylor
Executive Chairman11yrsAU$1.22m4.9%
A$ 110.0m
Colin Biggin
COO & Non-Independent Executive Director5.1yrsAU$1.02m1.35%
A$ 30.4m
Michelle Parker
CEO, MD & Executive Directorless than a yearsin datos0.34%
A$ 7.6m
Christopher Roberts
Non-Executive Director8.7yrsAU$86.88k5.66%
A$ 127.0m
Thomas Ramdahl
Non-Executive Director5.7yrsAU$86.88k0.22%
A$ 5.0m
Neal Shore
Member of Scientific Advisory Board2.5yrssin datossin datos
Rosanne Robinson
Lead Independent Non-Executive Director14.1yrsAU$95.72k0.056%
A$ 1.2m
Jason Lewis
Member of Scientific Advisory Boardno datasin datossin datos
Oliver Sartor
Member of Scientific Advisory Board4.7yrssin datossin datos
Paul Donnelly
Member of Scientific Advisory Boardno datasin datossin datos
Andrei Iagaru
Member of Scientific Advisory Board2.6yrssin datossin datos
Louise Emmett
Member of Scientific Advisory Board2.4yrssin datossin datos

4.9yrs

Permanencia media

Junta con experiencia: La junta directiva de CU6 se considera experimentada (4.9 años de antigüedad promedio).